Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumor × Vemurafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 63 Neoplasms 23 Neoplasm Metastasis 13 Colorectal Neoplasms 7 Thyroid Neoplasms 5 Skin Neoplasms 5 Multiple Myeloma 5 Lymphoma, Non-Hodgkin 5 Thyroid Cancer, Papillary 4 Leukemia, Hairy Cell 4 Hematologic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Sarcoma 3 Pancreatic Neoplasms 3 Glioma 3 Breast Neoplasms 3 Wilms Tumor 2 Thyroid Carcinoma, Anaplastic 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Recurrence 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Histiocytosis, Langerhans-Cell 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡